Trial Outcomes & Findings for Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy (NCT NCT05374876)
NCT ID: NCT05374876
Last Updated: 2026-07-08
Results Overview
The number of participants reported to have chemotherapy-induced peripheral neuropathy (CIPN) as measured by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
COMPLETED
NA
49 participants
Time of consent until the time of onset of CIPN of the hands or through 84 days of treatment
2026-07-08
Participant Flow
Participant milestones
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Overall Study
STARTED
|
24
|
25
|
|
Overall Study
COMPLETED
|
21
|
19
|
|
Overall Study
NOT COMPLETED
|
3
|
6
|
Reasons for withdrawal
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
2
|
|
Overall Study
Started Prohibited Medication
|
1
|
1
|
|
Overall Study
Hospitalization
|
1
|
0
|
|
Overall Study
Patients voluntary unblinding
|
0
|
2
|
|
Overall Study
Change in chemotherapy regimen
|
0
|
1
|
Baseline Characteristics
Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy
Baseline characteristics by cohort
| Measure |
Investigational Hand Therapy (IHT)] Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Total
n=40 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=9 Participants
|
5 Participants
n=27 Participants
|
13 Participants
n=267 Participants
|
|
Age, Categorical
>=65 years
|
13 Participants
n=9 Participants
|
14 Participants
n=27 Participants
|
27 Participants
n=267 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=9 Participants
|
8 Participants
n=27 Participants
|
17 Participants
n=267 Participants
|
|
Sex: Female, Male
Male
|
12 Participants
n=9 Participants
|
11 Participants
n=27 Participants
|
23 Participants
n=267 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
1 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
White
|
20 Participants
n=9 Participants
|
19 Participants
n=27 Participants
|
39 Participants
n=267 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
2 Participants
n=267 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
19 Participants
n=9 Participants
|
19 Participants
n=27 Participants
|
38 Participants
n=267 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Weight (kg)
|
76.8 kilograms
STANDARD_DEVIATION 16.3 • n=9 Participants
|
79.3 kilograms
STANDARD_DEVIATION 19.7 • n=27 Participants
|
78.0 kilograms
STANDARD_DEVIATION 17.8 • n=267 Participants
|
|
Height (cm)
|
172.5 centimeters
STANDARD_DEVIATION 11.3 • n=9 Participants
|
175.1 centimeters
STANDARD_DEVIATION 11.2 • n=27 Participants
|
173.7 centimeters
STANDARD_DEVIATION 11.2 • n=267 Participants
|
|
Body Mass Index (BMI)
|
25.6 kg/m^2
STANDARD_DEVIATION 4.1 • n=9 Participants
|
25.7 kg/m^2
STANDARD_DEVIATION 4.7 • n=27 Participants
|
25.6 kg/m^2
STANDARD_DEVIATION 4.3 • n=267 Participants
|
|
Cancer Metastatic
|
14 Participants
n=9 Participants
|
8 Participants
n=27 Participants
|
22 Participants
n=267 Participants
|
|
Cancer Non-Metastatic
|
7 Participants
n=9 Participants
|
11 Participants
n=27 Participants
|
18 Participants
n=267 Participants
|
PRIMARY outcome
Timeframe: Time of consent until the time of onset of CIPN of the hands or through 84 days of treatmentThe number of participants reported to have chemotherapy-induced peripheral neuropathy (CIPN) as measured by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
|
6 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Time of consent until the time of onset of CIPN of the hands or through 84 days of treatmentPopulation: Participants who did not report CIPN were censored from this analysis (n=15 investigational arm; n=15 traditional arm).
The mean time-to-event for chemotherapy-induced peripheral neuropathy CIPN) onset, as measured by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, is reported here. The analysis was produced using the Kaplan-Meier method.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=6 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=4 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Mean Time-to-Event for Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset
|
76.0 Days
Interval 68.5 to 83.6
|
75.8 Days
Interval 68.5 to 83.2
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyThe average pain score for hand pain among participants. Participants were tested at 5 visits throughout the study, and the 5 visits were averaged to produce a single score per participant. The average of the single score among participants is reported here. Hand pain was measured using the Visual Analog Scale (VAS) to measure pain intensity. This scale consists of a 10-cm horizontal line with "no pain" (score = 0 cm) on the left and "worst pain imaginable" (score = 10 cm) on the right. Participants mark their pain on the line, and the score is measured in centimeters.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Average Pain Score for Hand Pain
|
0 VAS Pain Score (cm)
Standard Deviation 0
|
0 VAS Pain Score (cm)
Standard Deviation 0
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyMotor function and symptoms among participants were measured using the QuickDASH questionnaire. This is an 11-item questionnaire used to monitor physical function and symptoms over time in people with upper-extremity musculoskeletal disorders. QuickDASH outputs a total functionality score ranging from 0 (no disability) to 100 (most severe disability). Questions related to daily activities, interference of social activities, limitations to work, and severity of symptoms are scored on a 5-point Likert scale (1 - no difficulty, 2 - mild difficulty, 3 - moderate difficulty, 4 - severe difficulty, 5 - unable). Responses are input into the following mathematical formula to output the total functionality score: \[(Sum of n responses / n - 1) \* 25\]. Scores of 0 - 30 are interpreted as mild to no disability, 31 - 60 moderate disability, and 61 to 100 as severe disability.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Average Motor Function and Symptoms [QuickDASH Score]
Visit 1
|
7.36 QuickDASH Score
Standard Deviation 10.31
|
7.06 QuickDASH Score
Standard Deviation 8.26
|
|
Average Motor Function and Symptoms [QuickDASH Score]
Visit 2
|
6.06 QuickDASH Score
Standard Deviation 9.27
|
7.49 QuickDASH Score
Standard Deviation 10.02
|
|
Average Motor Function and Symptoms [QuickDASH Score]
Visit 3
|
6.49 QuickDASH Score
Standard Deviation 9.43
|
6.10 QuickDASH Score
Standard Deviation 8.80
|
|
Average Motor Function and Symptoms [QuickDASH Score]
Visit 4
|
8.01 QuickDASH Score
Standard Deviation 10.51
|
7.84 QuickDASH Score
Standard Deviation 11.72
|
|
Average Motor Function and Symptoms [QuickDASH Score]
Visit 5
|
5.30 QuickDASH Score
Standard Deviation 7.95
|
6.20 QuickDASH Score
Standard Deviation 10.05
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyPopulation: Study participation ended if/when participants became symptomatic; therefore, some participants did not complete all of the study visits. Additionally, clinical circumstances affected battery completion in a limited number of participants. Number of participants not included in this analysis are as follows: visit 1 - n=1 investigational arm \[right arm only\]; visit 4 - n=3 investigational arm, n=1 traditional arm; visit 5 - n=6 investigational arm, n=2 traditional arm.
The number of participants with positive or negative peripheral nerve tolerance is reported here for both right and left arms as measured by the elevated arm stress test (EAST). EAST is a clinical provocation maneuver and is performed by holding the arms in a position of 90 degrees of abduction and external rotation ("stick-up position"). The patient then opens and closes the hands slowly for a period of 3 minutes. Reproduction of symptoms in the entire extremity or rapid fatigue of the extremity constitutes a positive test result. No reproduction of symptoms or rapid fatigue constitutes a negative result. Patients with thoracic outlet syndrome (TOS) typically have a positive test.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 1 - Right Arm · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 1 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 2 - Right Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 2 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 3 - Right Arm · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 3 - Right Arm · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 4 - Right Arm · Negative
|
18 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 4 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 5 - Right Arm · Negative
|
15 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 5 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 1 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 1 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 2 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 2 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 3 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 3 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 4 - Left Arm · Negative
|
18 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 4 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 5 - Left Arm · Negative
|
15 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Peripheral Nerve Tolerance at the Thoracic Level of the Right and Left Arm [Elevated Arm Stress Test (EAST)]
Visit 5 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyPopulation: Study participation ended if/when participants became symptomatic; therefore, some participants did not complete all of the study visits. Additionally, clinical circumstances affected battery completion in a limited number of participants. Number of participants not included in this analysis are as follows: visit 4 - n=3 investigational arm, n=1 traditional arm; visit 5 - n=6 investigational arm, n=2 traditional arm.
The number of participants with positive or negative median nerve irritation at the right and left wrist as measured by Phalen's test. This test is a neurological physical exam that involves passive flexion of the wrist for 15 to 60 seconds and reporting numbness/tingling. A positive test produces numbness and tingling in the distribution of the median nerve, while a negative test produces no numbness or tingling.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 1 - Right Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 1 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 2 - Right Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 2 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 3 - Right Arm · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 3 - Right Arm · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 4 - Right Arm · Negative
|
17 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 4 - Right Arm · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 5 - Right Arm · Negative
|
15 Participants
|
15 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 5 - Right Arm · Positive
|
0 Participants
|
2 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 1 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 1 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 2 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 2 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 3 - Left Arm · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 3 - Left Arm · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 4 - Left Arm · Negative
|
18 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 4 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 5 - Left Arm · Negative
|
15 Participants
|
16 Participants
|
|
Number of Participants With Positive or Negative Median Nerve Irritation at the Right and Left Wrist [Phalen's Test]
Visit 5 - Left Arm · Positive
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyPopulation: Study participation ended if/when participants became symptomatic; therefore, some participants did not complete all of the study visits. Additionally, clinical circumstances affected battery completion in a limited number of participants. Number of participants not included in this analysis are as follows: visit 4 - n=3 investigational arm, n=1 traditional arm; visit 5 - n=6 investigational arm, n=2 traditional arm.
The number of participants with positive or negative ulnar nerve compression at the right and left arm as measured by the elbow flexion test. With the shoulder in neutral position, manual pressure is applied to the ulnar nerve in the cubital tunnel as the elbow is placed in terminal flexion with the forearm supported in supination. The wrist is maintained in a neutral position. The position is held for 60 seconds. A positive test reports numbness, tingling, or shooting pain in the forearm, hand, or fingers. A negative test reports no numbness, tingling, or shooting pain in the forearm, hand, or fingers.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 1 - Right Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 1 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 2 - Right Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 2 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 3 - Right Arm · Negative
|
21 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 3 - Right Arm · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 4 - Right Arm · Negative
|
18 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 4 - Right Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 5 - Right Arm · Negative
|
15 Participants
|
16 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 5 - Right Arm · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 1 - Left Arm · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 1 - Left Arm · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 2 - Left Arm · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 2 - Left Arm · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 3 - Left Arm · Negative
|
21 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 3 - Left Arm · Positive
|
0 Participants
|
2 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 4 - Left Arm · Negative
|
18 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 4 - Left Arm · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 5 - Left Arm · Negative
|
15 Participants
|
16 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Compression at the Right and Left Arm [Elbow Flexion Test]
Visit 5 - Left Arm · Positive
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyPopulation: Study participation ended if/when participants became symptomatic; therefore, some participants did not complete all of the study visits. Additionally, clinical circumstances affected battery completion in a limited number of participants. Number of participants not included in this analysis are as follows: visit 4 - n=2 investigational arm, n=1 traditional arm; visit 5 - n=6 investigational arm, n=2 traditional arm.
The number of participants with positive or negative ulnar nerve injury at the right and left cubital tunnel as measured by Tinel's test. Tinel's test is a neurological physical exam administered as follows: with placing the patient's elbow fully flexed and the wrist held in neutral position, the examiner taps over the ulnar nerve at the cubital tunnel. A positive result causes tingling or pain, while a negative result causes no tingling or pain.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 3 - Right Cubital Tunnel · Positive
|
1 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 1 - Right Cubital Tunnel · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 1 - Right Cubital Tunnel · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 2 - Right Cubital Tunnel · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 2 - Right Cubital Tunnel · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 3 - Right Cubital Tunnel · Negative
|
20 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 4 - Right Cubital Tunnel · Negative
|
19 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 4 - Right Cubital Tunnel · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 5 - Right Cubital Tunnel · Negative
|
15 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 5 - Right Cubital Tunnel · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 1 - Left Cubital Tunnel · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 1 - Left Cubital Tunnel · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 2 - Left Cubital Tunnel · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 2 - Left Cubital Tunnel · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 3 - Left Cubital Tunnel · Negative
|
21 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 3 - Left Cubital Tunnel · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 4 - Left Cubital Tunnel · Negative
|
19 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 4 - Left Cubital Tunnel · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 5 - Left Cubital Tunnel · Negative
|
15 Participants
|
16 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Cubital Tunnel [Tinel's Test]
Visit 5 - Left Cubital Tunnel · Positive
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Visit 1: between consent and day 1 of chemotherapy; Visit 2: between days 8 and 15 of chemotherapy; Visit 3: between days 22 and 29 of chemotherapy; Visit 4: between days 50 and 57 of chemotherapy; Visit 5: at end of studyPopulation: Study participation ended if/when participants became symptomatic; therefore, some participants did not complete all of the study visits. Additionally, clinical circumstances affected battery completion in a limited number of participants. Number of participants not included in this analysis are as follows: visit 4 - n=2 investigational arm, n=1 traditional arm; visit 5 - n=6 investigational arm, n=2 traditional arm.
The number of participants with positive or negative ulnar nerve injury at the right and left volar wrist as measured by Tinel's test. Tinel's test is a neurological physical exam administered as follows: with placing the patient's elbow fully flexed and the wrist held in neutral position, the examiner taps over the ulnar nerve at the volar wrist. A positive result causes tingling or pain, while a negative result causes no tingling or pain.
Outcome measures
| Measure |
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
n=21 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
n=19 Participants
Hand Therapy Until CIPN: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
|
|---|---|---|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 1 - Right Volar Wrist · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 1 - Right Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 2 - Right Volar Wrist · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 2 - Right Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 3 - Right Volar Wrist · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 3 - Right Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 4 - Right Volar Wrist · Negative
|
19 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 4 - Right Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 5 - Right Volar Wrist · Negative
|
15 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 5 - Right Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 1 - Left Volar Wrist · Negative
|
20 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 1 - Left Volar Wrist · Positive
|
1 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 2 - Left Volar Wrist · Negative
|
21 Participants
|
19 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 2 - Left Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 3 - Left Volar Wrist · Negative
|
21 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 3 - Left Volar Wrist · Positive
|
0 Participants
|
1 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 4 - Left Volar Wrist · Negative
|
19 Participants
|
18 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 4 - Left Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 5 - Left Volar Wrist · Negative
|
15 Participants
|
17 Participants
|
|
Number of Participants With Positive or Negative Ulnar Nerve Injury at the Right and Left Volar Wrist [Tinel's Test]
Visit 5 - Left Volar Wrist · Positive
|
0 Participants
|
0 Participants
|
Adverse Events
Investigational Hand Therapy (IHT) Intervention Targeting the Nervous System
Traditional Occupational Therapy Intervention Targeting Compensatory Strategies (TOT)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Gayle Jameson, MSN, ACNP-BC, AOCN
HonorHealth Research Institute
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place